R&D Trends

Grünenthal, Nordic Bioscience, Argenta collaborate

Wednesday, October 21, 2015

Germany-based Grünenthal, Denmark-based Nordic Bioscience and U.K.-based Argenta Discovery 2009, a Charles River company, are collaborating to improve the R&D of therapeutic approaches in multi-organ fibrosis. With a particular focus on fast-progressing patient subpopulations, the collaboration aims to develop new and improved preclinical and clinical assays to optimize the identification of new therapies.

[Read More]

GSK, UCSF researchers partner

Wednesday, October 21, 2015

Researchers from GlaxoSmithKline and the University of California, San Francisco, will work together to accelerate promising basic science in cancer, obesity and infectious diseases toward new drugs. 

[Read More]

Olympus launches R&D group

Monday, October 19, 2015

Olympus has launched a U.S.-based R&D organization dedicated to helping meet the needs of researchers in the U.S. and Canada whose studies require customized technology solutions to meet advanced microscopy and imaging needs.

[Read More]

PDF, APDA cultivate future Parkinson’s researchers

Friday, October 16, 2015

The Parkinson’s Disease Foundation (PDF) and the American Parkinson Disease Association (APDA) are collaborating on Summer Student Fellowships to support research that will help solve, treat and end Parkinson’s disease. The collaboration expands opportunities for undergraduates and medical students to gain early exposure to careers in Parkinson’s by conducting 10-week research fellowships with established leaders in the field. The collaboration reflects PDF and APDA’s shared commitment to cultivating students’ early interest and leadership in Parkinson’s research.

[Read More]

Bristol-Myers Squibb, Five Prime collaborate

Thursday, October 15, 2015

Bristol-Myers Squibb and Five Prime Therapeutics have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008, which is in phase I development for immunology and oncology indications. The agreement replaces the companies’ existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor types.

[Read More]

CDC, Edico Genome partner on DRAGEN Hardware Platform

Monday, October 12, 2015

The Centers for Disease Control and Prevention, through the National Center for Emerging and Zoonotic Infectious Diseases, Office of Advanced Molecular Detection (OAMD), and Edico Genome have entered into a research collaboration to evaluate the performance of Edico Genome’s DRAGEN hardware platform. The goal of this research collaboration is to evaluate the utility of the Edico Genome DRAGEN platform for public health and infectious disease applications. This collaboration also will focus on co-developing the databases, configurations and parameters to optimize the hardware platform for microbial applications.

[Read More]